caa a22 4500 465786650 CHVBK 20180323112011.0 cr unu---uuuuu 170327e19901101xx s 000 0 eng 10.1007/BF00833011 doi (NATIONALLICENCE)springer-10.1007/BF00833011 Rapid background reduction of circulating sodium iodide I 125-labelled Pisum sativum agglutinin used as a tumor-imaging radiopharmaceutical by the chemically galactosylated antibody [Elektronische Daten] [Shuji Kojima, Kazuhiko Kubota, Akiko Kubodera, Masayoshi Imagawa, Hasn Gabius] Influence on the clearance of background radioactivity from the blood was studied by using a chemically galactosylated antibody to the radiopharmaceutical. Sodium iodide I 125-labelledPisum sativum agglutinin (125I-PSA) was used as the model tumor-imaging radiopharmaceutical in this series of experiments. Rabbit (anti-PSA) immunoglobulin G (IgG) was chemically galactosylated with varying amounts of cyanomethylgalactose. Galactose concentration ranged from 11 to 17 mol/mol protein. Antibody activity was not affected by chemical galactosylation under the experimental conditions used. Blood clearance of the galactosylated anti-PSA (GAP) in normal mice was enhanced to varying degrees, depending on the degree of galactosylation; similarly, liver uptake was increased with the degree of galactosylation. Following injection of125I-PSA in normal mice, the lectin was rapidly removed from the blood by subsequent injection of GAP. Increased hepatic uptake of the complex (lectin-galactosylated antibody) via protein-carbohydrate recognition caused the pronounced decrease in the125I-PSA blood level. The effective time for125I-PSA removal was as short as 15 min. The potency was dependent on the degree of galactosylation of the antibody. In sarcoma 180 (S-180) tumorbearing mice, the capacity for blood clearance of125I-PSA was also positively correlated to the degree of galactosylation. Moreover, the variation in the delivered dose ratio of antibody to lectin proved to lead to a further increase in background clearance. As a result, especially the tumor: blood ratio was significantly improved by a single administration of chemically galactosylated antibody, as compared with the value measured in the presence of unmodified antibody. These initial studies suggest that administration of GAP may improve nuclear imaging with radiopharmaceuticals. Springer-Verlag, 1990 Lectin nationallicence Tumor nationallicence Glycosylated antibody nationallicence Radiopharmaceuticals nationallicence Kojima Shuji Research Institute for Biosciences, Science University of Tokyo, 2669 Yamazaki, 278, Noda-shi, Chiba, Japan aut Kubota Kazuhiko Research Institute for Biosciences, Science University of Tokyo, 2669 Yamazaki, 278, Noda-shi, Chiba, Japan aut Kubodera Akiko Research Institute for Biosciences, Science University of Tokyo, 2669 Yamazaki, 278, Noda-shi, Chiba, Japan aut Imagawa Masayoshi Faculty of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita Osaka, Japan aut Gabius Hasn Abteilung Chemie, Max-Planck-Institut für Experimentelle Medizin, D-3400, Göttingen, Germany aut European Journal of Nuclear Medicine Springer-Verlag 16/11(1990-11-01), 781-786 0340-6997 16:11<781 1990 16 259 https://doi.org/10.1007/BF00833011 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00833011 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kojima Shuji Research Institute for Biosciences, Science University of Tokyo, 2669 Yamazaki, 278, Noda-shi, Chiba, Japan aut NATIONALLICENCE 700 1- Kubota Kazuhiko Research Institute for Biosciences, Science University of Tokyo, 2669 Yamazaki, 278, Noda-shi, Chiba, Japan aut NATIONALLICENCE 700 1- Kubodera Akiko Research Institute for Biosciences, Science University of Tokyo, 2669 Yamazaki, 278, Noda-shi, Chiba, Japan aut NATIONALLICENCE 700 1- Imagawa Masayoshi Faculty of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita Osaka, Japan aut NATIONALLICENCE 700 1- Gabius Hasn Abteilung Chemie, Max-Planck-Institut für Experimentelle Medizin, D-3400, Göttingen, Germany aut NATIONALLICENCE 773 0- European Journal of Nuclear Medicine Springer-Verlag 16/11(1990-11-01), 781-786 0340-6997 16:11<781 1990 16 259 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer